SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Bafna Pharmaceuticals declines on widening net loss to Rs 2.08 crore in Q4

01 Jun 2012 Evaluate

Bafna Pharmaceuticals is currently trading at Rs. 49.00, down by 0.25 points or 0.51% from its previous closing of Rs. 49.25 on the BSE. 

The scrip opened at Rs. 49.15 and has touched a high and low of Rs. 49.15 and Rs. 49.00 respectively. So far 4496 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 55.95 on 10-Jun-2011 and a 52 week low of Rs. 30.70 on 16-Dec-2011.

Last one week high and low of the scrip stood at Rs. 51.40 and Rs. 49.00 respectively. The current market cap of the company is Rs. 90.25 crore.

The promoters holding in the company stood at 40.26% while Non-Institutions held 59.74% stake in the company. 

Bafna Pharmaceuticals has reported a widening of its standalone net loss to Rs 2.08 crore for the quarter ended March 31, 2012 as compared to a net loss of Rs 0.85 crore over the same period previous fiscal. However, the net sales of the company increased by 10.57% to Rs 32.73 crore in the quarter under review from Rs 29.60 crore in same period year ago.

For the full year, the company’s net profit declined by 38.05% at Rs 20.74 crore against Rs 33.48 crore for the previous fiscal however, net sales of the company rose 19.43% to Rs 120.98 crore for FY12 from Rs 101.30 crore for FY11.

Bafna Pharma Share Price

132.05 -0.60 (-0.45%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×